The Food and Drug Administration blocked approval of a new skin cancer treatment that shrank or eliminated tumors in roughly a third of trial patients, and the decision has left doctors, patients, and investors struggling to understand what the agency's standards even are anymore.
Replimune's RP1, a drug designed to treat melanoma, was denied accelerated approval after the FDA said it could not determine whether the treatment's positive results came from RP1 itself or from Opdivo, the drug it was paired with in the trial. The agency pointed to the absence of a control arm, a comparison group receiving standard treatment, as a core deficiency in the 140-person clinical trial.
The denial matters far beyond one company. Melanoma is the fifth most commonly diagnosed cancer in the United States, with about 112,000 new cases each year. The American Cancer Society projects roughly 8,500 Americans will die from it this year alone. Doctors who treated patients in the trial say the FDA just took away a lifeline, and they aren't sure why the rules seem to keep changing.
Trisha Wise-Draper, a dermatologist at the University of Cincinnati who enrolled patients in the RP1 trial, told CBS News that some of her patients responded so well they no longer showed evidence of melanoma.
"It was devastating news."
Wise-Draper pushed back directly on the FDA's criticism of the trial design. She argued that assigning melanoma patients to a control arm, effectively denying them the experimental treatment, would have crossed an ethical line.
"Having a control arm would have been unethical."
Eric Whitman, medical director of Atlantic Health System's oncology service, put the stakes in blunt terms. He estimated as many as 2,500 patients per year could be saved if RP1 performed in broader use the way it did in the trial.
"This is life or death for maybe 2,000 patients."
Whitman raised a second, equally pressing concern: whether Replimune can survive long enough to finish a larger trial. The company told reporters it is firing more than half its staff and closing some operations. An accelerated approval, Whitman said, would have persuaded investors to provide enough cash to complete a bigger study. Without it, the drug's future is in doubt.
The RP1 denial did not happen in a vacuum. It landed during a period of extraordinary instability at the FDA under Commissioner Marty Makary, who resigned this week after roughly 13 months in charge.
Makary's tenure was marked by ambitious promises: ending animal testing, aggressively implementing artificial intelligence, and reducing the standard number of required clinical trials from two to one. But the gap between those promises and the agency's actual behavior on individual drug decisions left the pharmaceutical world confused about what the FDA expects.
Steven Grossman, a regulatory consultant and former official at the Department of Health and Human Services, described an agency whose internal compass has been spinning.
"People have to speculate about the standards and processes by which the agency makes decisions. And that uncertainty is bad for everybody, patients and sponsors and investors."
Grossman said the FDA's direction under Makary had been "swinging in every conceivable direction." The agency fired roughly 4,000 staffers at the start of the Trump administration. Makary promised to hire thousands back, but Grossman questioned the feasibility: "What magic trick will get that done?"
The broader turmoil inside HHS has not been limited to the FDA. Multiple departures across the health bureaucracy have underscored persistent internal friction under HHS Secretary Robert F. Kennedy Jr.
What makes the RP1 denial so difficult for the medical community to accept is the FDA's own track record. Merck's Keytruda, now one of the most widely used cancer drugs in the world, was approved to treat melanoma roughly 12 years ago based on a single-arm trial design. That is the same type of trial the FDA just rejected for RP1.
The FDA's accelerated approval program, now three decades old, was built precisely for situations like this: allowing promising drugs onto the market based on early evidence while larger confirmatory trials continue. Whitman pointed to the contradiction directly.
"It's very inconsistent; it's all over the place. The inconsistency is part of the concern."
Paul Kim, a pharmaceutical industry consultant in Boston and former FDA staffer, acknowledged that Replimune "arguably could have found an ethical way to set up a control arm." But he said the FDA could have handled the situation differently, granting a "provisional yes" through accelerated approval while requiring stronger data later. The whole point of the program, Kim said, is to "take a gamble."
Kim described the denial as "a recalibration of how confident sponsors can be with similar studies." That recalibration carries real consequences. Drug companies designing future trials will now have to guess whether the FDA's old standards, Makary's stated standards, or some new set of standards will apply when their applications arrive.
Reports surrounding whether Makary resigned or was pushed out only add to the uncertainty about the agency's direction going forward.
Hanging over the entire episode is the role of Vinay Prasad, an oncologist who held various leadership roles at the FDA under Makary. Prasad was fired, then rehired last summer, and repeatedly intervened in approval processes for drugs and vaccines that would normally be decided by lower-ranking FDA professionals.
Prasad resigned for good on May 1, three weeks after the Replimune decision. He did not respond to requests for comment.
Kim raised the question many in the industry are asking but cannot answer.
"There's this lingering question of whether this was Vinay's last stand, or an objective decision made by careful scientists."
That is not a small question. If the RP1 denial was driven by sound science, the FDA should be able to explain it clearly and consistently. If it was shaped by the personal priorities of a departing official, then melanoma patients paid the price for internal politics.
In a May 5 CNBC interview, Makary accused Replimune of "corruption" and "engaging in corporate spin." He framed the denial as a straightforward regulatory call.
"I don't work for Replimune. I work for the American people."
Kennedy backed Makary during a congressional budget hearing, though he mistakenly claimed that patients in the Replimune trial had also received chemotherapy, an error that did not inspire confidence in the administration's grasp of the details.
The Wall Street Journal's editorial board assailed the ruling, warning it "will have a chilling effect on drug development." Aaron Kesselheim, a Harvard Medical School professor and expert on the drug industry, identified a deeper contradiction in the FDA's posture: the agency has been signaling it wants to reduce the evidence needed for drug approval, while simultaneously making it harder to get vaccines approved.
"The FDA is sending signals that it wants to even further reduce the evidence needed to support drug approval. Of course, if we're talking about vaccines, the total opposite is the case. FDA has been taking real steps to make it harder to get vaccines approved."
That two-track approach, looser for drugs, tighter for vaccines, raises fair questions about whether science or ideology is driving the agency's decisions. The FDA's broader policy shifts under Makary, including fast-tracking certain experimental therapies, make the RP1 rejection stand out even more sharply.
Evan Seigerman, who leads healthcare research at BMO Capital Markets, captured the frustration felt across the medical and financial communities.
"The unfortunate thing is that there has been so much chaos at FDA that this Replimune decision, which may have needed to happen, has gotten mired in the controversy."
That is perhaps the most damning assessment of all. Even people willing to accept that the FDA might have had legitimate scientific reasons to deny RP1 cannot separate the decision from the institutional chaos surrounding it. When an agency that regulates 20 percent of U.S. consumer spending cannot clearly communicate its own standards, everyone suffers, patients, companies, investors, and the public trust that makes the whole system work.
Kim put it plainly: "All the norms have been thrown out the window, so we don't know what underlines an agency decision. Even when there are legitimate scientific and regulatory reasons why a drug will not be approved, we're left guessing whether it's legitimate grounds or just a political play."
Replimune did not respond to repeated requests for comment. Makary did not respond either. Prasad is gone. And roughly 2,000 melanoma patients are left waiting for a treatment that may never reach them, not because the science failed, but because the institution charged with evaluating it could not get out of its own way.
An agency that cannot explain its own rules has no business deciding who lives and who dies.
